EXACT SCIENCES CORP (EXAS) Stock Price, Quote, News and Overview
NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
EXAS Quote, Performance and Key Statistics
52.34
-0.2 (-0.38%)
The current stock price of EXAS is 52.34 USD. In the past month the price decreased by -9.46%. In the past year, price increased by 16.7%.
EXAS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.06 | 327.65B | ||
| AMGN | AMGEN INC | 13.95 | 155.74B | ||
| GILD | GILEAD SCIENCES INC | 13.95 | 134.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.59 | 55.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.72B | ||
| ARGX | ARGENX SE - ADR | 93.55 | 32.85B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.47 | 27.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.10B | ||
| NTRA | NATERA INC | N/A | 23.35B | ||
| BIIB | BIOGEN INC | 8 | 18.54B | ||
| INSM | INSMED INC | N/A | 18.12B |
Related stock screener links
About EXAS
Company Profile
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Company Info
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN 53719 US
CEO: Kevin T. Conroy
Employees: 6950
Phone: 16082845700
EXACT SCIENCES CORP / EXAS FAQ
What is the stock price of EXACT SCIENCES CORP today?
The current stock price of EXAS is 52.34 USD. The price decreased by -0.38% in the last trading session.
What is the ticker symbol for EXACT SCIENCES CORP stock?
The exchange symbol of EXACT SCIENCES CORP is EXAS and it is listed on the Nasdaq exchange.
On which exchange is EXAS stock listed?
EXAS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EXACT SCIENCES CORP stock?
34 analysts have analysed EXAS and the average price target is 70.68 USD. This implies a price increase of 35.04% is expected in the next year compared to the current price of 52.34. Check the EXACT SCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EXACT SCIENCES CORP worth?
EXACT SCIENCES CORP (EXAS) has a market capitalization of 9.87B USD. This makes EXAS a Mid Cap stock.
How many employees does EXACT SCIENCES CORP have?
EXACT SCIENCES CORP (EXAS) currently has 6950 employees.
What are the support and resistance levels for EXACT SCIENCES CORP (EXAS) stock?
EXACT SCIENCES CORP (EXAS) has a support level at 52.33 and a resistance level at 54.14. Check the full technical report for a detailed analysis of EXAS support and resistance levels.
Is EXACT SCIENCES CORP (EXAS) expected to grow?
The Revenue of EXACT SCIENCES CORP (EXAS) is expected to grow by 12.81% in the next year. Check the estimates tab for more information on the EXAS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EXACT SCIENCES CORP (EXAS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EXAS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EXAS, evaluating the profitability, health, valuation and growth aspects
- EXACT SCIENCES CORP (EXAS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EXACT SCIENCES CORP (EXAS) Sales and EPS estimates to see what analysts future expectations are.
- EXACT SCIENCES CORP (EXAS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EXACT SCIENCES CORP (EXAS) Insider and Institutional Ownership to learn about the owners and their transactions.
- EXACT SCIENCES CORP (EXAS) Stock Chart to make your own analysis
- EXACT SCIENCES CORP (EXAS) Latest news and press-releases to stay up to date.
Does EXACT SCIENCES CORP (EXAS) stock pay dividends?
EXAS does not pay a dividend.
When does EXACT SCIENCES CORP (EXAS) report earnings?
EXACT SCIENCES CORP (EXAS) will report earnings on 2025-07-29, after the market close.
What is the Price/Earnings (PE) ratio of EXACT SCIENCES CORP (EXAS)?
EXACT SCIENCES CORP (EXAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.51).
What is the Short Interest ratio of EXACT SCIENCES CORP (EXAS) stock?
The outstanding short interest for EXACT SCIENCES CORP (EXAS) is 5.73% of its float. Check the ownership tab for more information on the EXAS short interest.
EXAS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS is one of the better performing stocks in the market, outperforming 82.29% of all stocks.
EXAS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EXAS. The financial health of EXAS is average, but there are quite some concerns on its profitability.
EXAS Financial Highlights
Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -5.51. The EPS decreased by -317.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.86% | ||
| ROE | -42.55% | ||
| Debt/Equity | 0.97 |
EXAS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to EXAS. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 89.86% and a revenue growth 12.81% for EXAS